Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00605956
Other study ID # SPN-108-08
Secondary ID HTR Study #07-12
Status Completed
Phase Phase 1
First received January 21, 2008
Last updated July 31, 2008
Start date January 2008
Est. completion date February 2008

Study information

Verified date May 2008
Source ParaPRO LLC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Photoallergic reactions are assumed to be due to a delayed cell-mediated hypersensitivity response that requires the presence of ultraviolet irradiation. The predictive procedure is, therefore, based on modification of the Repeated Insult Patch Test (Kaidbey, 1991). Duplicate sets of patches of test articles are used with exposure of only one set to UV radiation and subsequent evaluation of both sets for skin reactions in order to compare irradiated versus non-irradiated test sites.


Description:

The study consists of of following phases: screening, induction, rest, challenge, and re-challenge (if necessary). The study will be conducted as a randomized, evaluator-blind test design.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date February 2008
Est. primary completion date February 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male or female subjects 18-65 years of age

- Has the ability to understand and has signed a written informed consent form and HIPAA authorization

- Females of childbearing potential must agree to use an adequate birth control

- Fitzpatrick (1988) skin type I, II, or III.

Exclusion Criteria:

- History of severe reactions from exposure to sunlight

- Known allergies or sensitivities to adhesives in patches, medical tape, or ingredients found in the test articles

- Inability to evaluate the skin in and around the test sites

- Diabetes requiring medication

- Clinical significant skin diseases which may contraindicate participation

- Asthma or any other severe respiratory disease requiring chronic medication

- Known immunological disorders such as HIV, AIDS, SLE and/or RA

- History, within the last six months, of current cancer, including skin cancer

- Mastectomy for cancer removal of lymph nodes draining test sites

- Epilepsy

- Pregnancy, lactation, or planning a pregnancy during the test period

- Chronic use of systemic antihistamine medication, or use within 14 days prior to Screening Visit

- Use of anti-inflammatory drugs (exception: acetaminophen and < 81 mg.day aspirin are permitted) within 2 days of Screening Visit

- Currently receiving allergy injections

- Currently taking or expecting to take any photosensitizing medications

- Use of immunosuppressive drugs

- Topical drugs used at the test sites within the last 7 days prior to screening

- Current participation in any clinical trial

- Participation in any patch test for irritation or sensitization or any test involving UV exposures within 4 wees of study start

- Use of any investigational therapy within the past 4 weeks.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
NatrOVA Creme Rinse - 1%
NatrOVA Creme Rinse - 1% spinosad
NatrOVA Creme Rinse Vehicle Only
NatrOVA Creme Rinse Vehicle - no spinosad
Blank Patch
Blank Patch

Locations

Country Name City State
United States Hill Top Research St. Petersburg Florida

Sponsors (1)

Lead Sponsor Collaborator
ParaPRO LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual grading of test site and assessments of adverse experiences Evaluations over a 6 week period Yes
See also
  Status Clinical Trial Phase
Completed NCT00988533 - A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age Phase 1
Completed NCT00672971 - Safety and Efficacy Study to Compare a 4% Dimethicone Foam and Nix Cream Rinse (1% Permethrin) in the Control of Head Lice N/A
Completed NCT00858481 - A Pilot Dose Ranging Study of Spinosad Creme Rinse Phase 2
Completed NCT03301649 - Clinical Endpoint Study of Ivermectin 0.5% Lotion Phase 3
Completed NCT00995124 - Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application Phase 4
Completed NCT00994422 - Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects Phase 2
Completed NCT03337490 - A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice Phase 3
Completed NCT06333054 - Safety and Efficacy of a Head Lice Shampoo N/A
Completed NCT02213055 - Pediatric Head Lice Study Product Comparison Phase 2
Completed NCT02974088 - Neem Lotion With Combing for Lice Phase 2
Recruiting NCT05379114 - Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation N/A
Completed NCT03617926 - A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product. N/A
Completed NCT01803581 - A Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice N/A
Completed NCT01066585 - A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation Phase 3
Completed NCT01068158 - A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects Phase 3
Completed NCT00857935 - A Safety and Efficacy Pilot Study Comparing NatrOVA Creme Rinse 1% and NIX Creme Rinse Phase 2
Completed NCT00301340 - Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice Phase 3
Completed NCT02061813 - Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion Phase 1
Completed NCT02062073 - Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion Phase 1
Completed NCT00479310 - Efficacy and Safety of Summers Non-Pesticide Lice Asphyxiator (L.A.)for the Treatment of Head Lice Phase 3

External Links